| Product Name | IFNb ELISA kit (Human) |
|---|---|
| Description | This assay has high sensitivity and excellent specificity for detection of Interferon Beta (IFNb). No significant cross-reactivity or interference between Interferon Beta (IFNb) and analogues was observed. |
| Synonyms | IFNB1; IFN-B; IFB; IFF; IFNB; Interferon Beta 1 Fibroblast |
| Method | Sandwich |
| Detection Range | 7.8-500pg/mL |
| Sensitivity | 2.7pg/mL |
| Target | IFNb |
| Specificity | This assay has high sensitivity and excellent specificity for detection of Interferon Beta (IFNb). No significant cross-reactivity or interference between Interferon Beta (IFNb) and analogues was observed. |
| Reactivity | Human |
| Sample Types | Serum, Plasma, Tissue Homogenates, Cell Lysates, Cell Culture Supernates And Other Biological Fluids |
| Reconstitution | 1.Prepare all reagents, samples and standards; 2.Add 100uL standard or sample to each well.Incubate 2 hours at 37℃; 3.Aspirate and add 100uL prepared Detection Reagent A.Incubate 1 hour at 37℃; 4.Aspirate and wash 3 times; 5.Add 100uL prepared Detection Reagent B.Incubate 30 minutes at 37℃; 6.Aspirate and wash 5 times; 7.Add 90uL Substrate Solution.Incubate 10-20 minutes at 37℃; 8.Add 50uL Stop Solution.Read at 450nm immediately. |
| Uniprot | P01574 |
| Storage | 4°C for 1 month/ -20°C for long-term(within shelf life) |
| Notes | Colormetric |
| References | Hepatitis B virus polymerase inhibits RIG-I- and Toll-like receptor 3-mediated beta interferon induction in human hepatocytes through interference with interferon regulatory factor 3 activation and dampening of the interaction between TBK1/IKKε and DDX3.;Impaired TLR3/IFN-β signaling in monocyte-derived dendritic cells from patients with acute-on-chronic hepatitis B liver failure: Relevance to the severity of liver damage;Training Modifies Innate Immune Responses in Blood Monocytes and in Pulmonary Alveolar Macrophages;Mannan binding lectin attenuates double-stranded RNA-mediated TLR3 activation and innate immunity;MicroRNA-30e* Suppresses Dengue Virus Replication by Promoting NF-κB–Dependent IFN Production;Complexes of DNA with the Antimicrobial Peptide LL37 Augment NK Cell Functions by Inducing Type I Interferon Production from Circulating Monocytes and Plasmacytoid Predendritic Cells;siRNA Targeting the 2A pro Genomic Region Prevents Enterovirus 71 Replication In Vitro;Cellular uptake of exogenous calcineurin B is dependent on TLR4/MD2/CD14 complexes, and CnB is an endogenous ligand of TLR4;Effects of IRF1 and IFN-β interaction on the M1 polarization of macrophages and its antitumor function;Host miR-146a promotes replication of human cytomegalovirus by suppressing type I IFN response in MRC-5 cells;MicroRNA-548j inhibits type I interferon production by targeting ZBTB11 in patients with chronic hepatitis B;Zika virus elicits inflammation to evade antiviral response by cleaving cGAS via NS1‐caspase‐1 axis;Evaluation of serum interferons in patients with age-related macular degeneration;Serodiagnosis of Human Bocavirus 1 Infection among Hospitalised Children with Lower Respiratory Tract Infection in Latvia;Scavenger receptor A impairs interferon response to HBV infection by limiting TRAF 3 ubiquitination through recruiting OTUB 1;Transferrin-dependent crosstalk between the intestinal tract and commensal microbes contributes for immune tolerance;Anti‐IFN‐α/‐ω neutralizing antibodies from COVID‐19 patients correlate with downregulation of IFN response and laboratory biomarkers of disease severity; |
| Supplier | Cloud Clone |
All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.